Teva said its investigational anti-IL-15 antibody, TEV-408/TEV-53408, met the primary endpoint in a Phase 2a celiac disease trial after a single subcutaneous dose.
The study reported statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo, along with improved inflammation markers and lower GI symptom scores.
No new safety signals were observed, and Teva framed the result as support for a broader 'pipeline-in-a-product' strategy across IL-15-driven diseases.
The result appears to strengthen the case for IL-15 as a drug target in celiac disease and may heighten interest in the broader IL-15 therapeutic market.
Earlier in 2025, the candidate had already received U.S. FDA Fast Track designation for celiac disease, signaling regulatory interest in the program.
Sources:
Teva Announces Positive Topline Results from Phase 2a Study in ...
Teva Announces Positive Topline Results from Phase 2a ...
Teva Celiac Disease Candidate Granted Fast Track ...
Teva's TEV-408 Hits Key Phase IIa Endpoint in Celiac ...
Teva (TEVA) announces positive topline results from Phase 2a study ...
Teva's immune disorder drug meets main goal in mid-stage trial
FDA Grants Fast Track Designation to Teva Celiac Disease ...
DEVELOPING TEV-53408 FOR THE TREATMENT OF ...
Teva's TEV '408 Clears Phase 2a Bar in Celiac Disease
TEV-'408 / Teva, Royalty - Vitiligo
Beneficial Effects of Human Anti-Interleukin-15 Antibody in Gluten ...
Teva gets FDA Fast Track for celiac disease drug TEV-53408